CYP2C18 Antibody (A-8): sc-518231

CYP2C18 Antibody (A-8) is a mouse monoclonal IgG2a kappa light chain antibody specific for an epitope mapping between amino acids 466-485 of CYP2C18 of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CYP2C18 monoclonal antibody (A-8) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing versatility for different experimental needs. CYP2C18 is a member of the cytochrome P450 superfamily, which plays a crucial role in the metabolism of various endogenous and exogenous compounds, including drugs and toxins. CYP2C18 is primarily located in the liver, where CYP2C18 facilitates the oxidative metabolism of fatty acids and steroid hormones, making CYP2C18 essential for maintaining metabolic homeostasis and drug clearance. Proper functioning of CYP2C18 is vital, as alterations in CYP2C18 activity can lead to significant pharmacokinetic variations among individuals, impacting drug efficacy and safety. Additionally, CYP2C18 is involved in the metabolism of certain therapeutic agents, and understanding CYP2C18 function can aid in personalized medicine approaches. With robust reactivity and multiple applications, anti-CYP2C18 antibody (A-8) is an invaluable tool for researchers studying drug metabolism and the physiological roles of cytochrome P450 enzymes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CYP2C18 Antibody (A-8) References:

1. Rapid detection of CYP2C18 genotypes by real-time fluorescence polymerase chain reaction.  |  Mizugaki, M., et al. 2000. J Pharm Pharmacol. 52: 199-205. PMID: 10714950
2. Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing.  |  Zhu-Ge, J., et al. 2002. World J Gastroenterol. 8: 888-92. PMID: 12378636
3. Complete absence of Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne syndrome.  |  Horibata, K., et al. 2004. Proc Natl Acad Sci U S A. 101: 15410-5. PMID: 15486090
4. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation.  |  Teresi, RE., et al. 2007. Am J Hum Genet. 81: 756-67. PMID: 17847000
5. Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression.  |  Löfgren, S., et al. 2008. Drug Metab Dispos. 36: 955-62. PMID: 18276835
6. First report of ovarian dysgerminoma in Cowden syndrome with germline PTEN mutation and PTEN-related 10q loss of tumor heterozygosity.  |  Cho, MY., et al. 2008. Am J Surg Pathol. 32: 1258-64. PMID: 18594467
7. PTEN hamartoma tumor syndromes.  |  Blumenthal, GM. and Dennis, PA. 2008. Eur J Hum Genet. 16: 1289-300. PMID: 18781191
8. Kabuki syndrome and trisomy 10p.  |  Utine, GE., et al. 2008. Genet Couns. 19: 291-300. PMID: 18990985
9. Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone.  |  Löfgren, S., et al. 2009. Drug Metab Dispos. 37: 1505-12. PMID: 19339376
10. Apparent late-onset Cockayne syndrome and interstitial deletion of the long arm of chromosome 10 (del(10)(q11.23q21.2)).  |  Fryns, JP., et al. 1991. Am J Med Genet. 40: 343-4. PMID: 1951442
11. Construction of a fused grid-based CYP2C18-Template system and its application to drug metabolism.  |  Yamazoe, Y. and Yoshinari, K. 2024. Drug Metab Pharmacokinet. 54: 100534. PMID: 38070310
12. Chromosomal location of two human genes encoding tetrahydrobiopterin-metabolizing enzymes: 6-pyruvoyl-tetrahydropterin synthase maps to 11q22.3-q23.3, and pterin-4 alpha-carbinolamine dehydratase maps to 10q22.  |  Thöny, B., et al. 1994. Genomics. 19: 365-8. PMID: 8188266

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CYP2C18 Antibody (A-8) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-CYP2C18 Antibody (A-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CYP2C18 Antibody (A-8) Specifications

Alternate Product Name: CYP2C18

Product Clone Name: A-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 466-485

Epitope Target: CYP2C18

Epitope Species: human

Product Reactivity/Detection: CYP2C18

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for CYP2C18 Antibody (A-8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin